Balleari E, Filiberti RA, Salvetti C, et al. Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: Aa propensity score‐matched analysis. Cancer Med. 2019;8:7567-7576.
Fenaux P, Santini V, Aloe Spiriti MA, et al. Randomized, double-blind, placebo-controlled, multicenter study evaluating epoetin alfa versus placebo in anemic patients with IPSS Low-Int1 risk MDS. Haematologica. 2016;101(suppl1):Abstract P248.
Platzbecker U, Symeonidis A, Oliva E, et al. ARCADE (20090160): a phase 3 randomized placebo-controlled double-blind trial of darbepoetin alfa in the treatment of anemia in patients with Llow or Iintermediate-1 risk myelodysplastic syndromes (MDS). Haematologica. 2016;101(suppl1):Abstract S128.
Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8:73483-73500.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454-2465.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Llow-/Iintermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765-3776.
Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988-2996.
Jädersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29:1971-1979.
Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549-1556.[Epub ahead of print].
Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140-151.
Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136:157-170.
Palomo L, Solé F. SF3B1: the lord of the rings in MDS. Blood. 2020;136:149-151.
Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64-69.
Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384-1395.
Remacha AÁF, Arrizabalaga B, Villegas A, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015;94:779-787.
Wong CAC, Wong SAY, Leitch HA. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: relation to infections and possible benefit of iron chelation therapy. Leuk Res. 2018;67:75-81.
Angelucci E, Li J, Greenberg P, et al. Iron chelation in transfusion-dependent patients with low- to Iintermediate-1-risk myelodysplastic syndromes: a randomized trial. Ann Intern Med. 2020;172:513-522.[Epub ahead of print].
Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017;130:1514-1522.
Garcia-Manero G, Gore SD, Kambhampati S, et al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016;30:889-896.
Garcia-Manero G, Scott BL, Cogle CR, et al. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leuk Res. 2018;72:79-85.
Stahl M, DeVeaux M, de Witte T, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2:1765-1772.
Henry DH, Glaspy J, Harrup RA, et al. Roxadustat (FG4592; ASP1517; AZD9941) in the treatment of anemia in patients with lower risk myelodysplastic syndrome (LR-MDS) and low red blood cell (RBC) transfusion burden (LTB). Blood. 2019;134(suppl1):Abstract 843.
Platzbecker U, Fenaux P, Steensma DP, et al. Treatment with imetelstat provides durable transfusion independence (TI) in heavily transfused non-del(5q) lower risk MDS (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA). EHA Library. 2020:Abstract S183.
Palumbo A, Palladino C. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf. 2012;3:255-266.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Valeria Santini, MD

Associate Professor of Hematology
MDS Unit, Hematology
AOUC University of Florence Medical School
Florence, Italy

Disclosures

Disclosure: Valeria Santini, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene; Bristol Myers Squibb; Janssen; Menarini; Novartis; Pfizer; Takeda
Served as a speaker or a member of a speakers bureau for: Celgene; Bristol Myers Squibb; Novartis

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Ryan Blanchard

Writer, WebMD Global, LLC

Disclosures

Disclosure: Ryan Blanchard has disclosed no relevant financial relationships.

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Novartis

Received grants for clinical research from: Janssen

CPD

Application of New Treatment Paradigms for Anemia in Lower Risk MDS: Practical Insights

Authors: Valeria Santini, MD
CPD Released: 11/11/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/11/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US professionals, specifically hematologists, involved in the care of patients with myelodysplastic syndrome (MDS).

The goal of this activity is to Increase knowledge and competence in the application of best practice treatment for patients with lower-risk MDS with transfusion dependent anemia.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical evidence on available treatment options for lower-risk MDS
Have greater competence related to
- Tailoring treatment for patients with transfusion-dependent lower-risk MDS

Disclosures

Faculty

Valeria Santini, MD

Associate Professor of Hematology
MDS Unit, Hematology
AOUC University of Florence Medical School
Florence, Italy

Disclosures

Disclosure: Valeria Santini, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene; Bristol Myers Squibb; Janssen; Menarini; Novartis; Pfizer; Takeda
Served as a speaker or a member of a speakers bureau for: Celgene; Bristol Myers Squibb; Novartis

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Ryan Blanchard

Writer, WebMD Global, LLC

Disclosures

Disclosure: Ryan Blanchard has disclosed no relevant financial relationships.

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Novartis

Received grants for clinical research from: Janssen

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Application of New Treatment Paradigms for Anemia in Lower Risk MDS: Practical Insights

Authors: Valeria Santini, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 11/11/2020

Valid for credit through: 11/11/2021, 11:59 PM EST

processing....

CPD Information Download Slides

Print
Like Tweet

Disclaimer

It is Medscape's policy to avoid the use of Brand names in CME activities. However, in an effort to be as clear as possible, the name for erythropoietin (EPO) products was used to apply to all ESA products. It is not meant to promote any particular product.

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Valeria Santini, MD

Editors

Sanneke Koekkoek

Ryan Blanchard

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Peer Reviewer

CPD

Application of New Treatment Paradigms for Anemia in Lower Risk MDS: Practical Insights

Target Audience and Goal Statement

Disclosures

Faculty

Valeria Santini, MD

Editors

Sanneke Koekkoek

Ryan Blanchard

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Application of New Treatment Paradigms for Anemia in Lower Risk MDS: Practical Insights